DBV Technologies S.A. (DBVT)
DBVT Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of DBV Technologies S.A. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DBV Technologies S.A. (“DBV” or the Company”) (NASDAQ: DBVT). The investigation concerns whether DBV and certain of its officers and/or directors have violated federal securities laws.
On March 16, 2020, DBV issued a press release disclosing that “the U.S. Food and Drug Administration (FDA) has informed the Company that during its ongoing review of the Biologics License Application (BLA) for investigational Viaskin™ Peanut, it has identified questions regarding efficacy, including the impact of patch-site adhesion.” DBV further advised investors that it “is in communication with the FDA regarding the potential submission of additional information on patch-site adhesion from its clinical program as well as long-term efficacy results from the three-year open-label extension study, PEOPLE, to answer FDA’s questions” and that while the Company “has received no additional information regarding the timeline of the BLA review . . . the submission of additional information to the FDA may constitute a major amendment to the BLA and could extend the target action date.” On this news, DBV’s stock price fell sharply during intraday trading on March 17, 2020.
If you are aware of any facts relating to this investigation, or purchased DBV shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.